About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNCT07477769

Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)

Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and the...

Lead sponsor: Assistance Publique - Hôpitaux de Paris•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Emmanuelle Bourrat, MD

CONTACT

01 42 49 90 90 emmanuelle.bourrat@aphp.fr

Jérôme Lambert, MD PhD

CONTACT

jerome.lambert@u-paris.fr

Sponsors

Lead Sponsor

Assistance Publique - Hôpitaux de Paris

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult patients (\> 18 years old)
•ARCI-type ichthyosis with NIPAL4 mutation (Nipal4-nEDD)

Exclusion Criteria

•Ichthyosis that has not been genotyped or with mutations in different genes
•Patients with concomitant inflammatory, infectious, or hematological conditions
•Individuals subject to legal protection measures or deprived of their liberty by judicial or administrative decision
•Individuals under guardianship/curatorship
•Opposition to the research

Related studies

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868 · Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and more

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100 · Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, and more

Active Not RecruitingPhase 1

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960 · Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, and more

Active Not RecruitingPhase 1

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

NCT05944562 · Mycosis Fungoides, Sezary Syndrome, and more

Active Not RecruitingPhase 1

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT03602157 · Lymphoma, Immune System Diseases, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment10

Start dateApr 2026

Last updatedMar 17, 2026

Condition

Sezary Syndrome Ichthyosis, Lamellar

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions